VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. George on Efficacy With PD-1 Inhibitor in Uterine Leiomyosarcoma

Suzanne George, MD
Published: Monday, May 01, 2017



Suzanne George, MD, assistant professor of Medicine, Harvard Medical School, clinical director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, discusses a study exploring the efficacy of a PD-1 inhibitor in patients with uterine leiomyosarcoma.

Recently published research was comprised of a collaborative effort between the sarcoma and genomics team at Dana-Farber Cancer Institute, which included a patient who achieved an exceptional response to the PD-1 inhibitor pembrolizumab (Keytruda). The patient received pembrolizumab as first-line therapy for metastatic recurrent uterine leiomyosarcoma, and had a dramatic response to the agent in multiple sites of disease—with the exception of a single site.

Researchers were ultimately able to resect that resistance site of disease, she adds. Tissue samples were gathered from her baseline tumor, which had a dramatic response, and the resistant tumor in an attempt to determine the factors for resistance. These 2 differences may help researchers understand why it became resistant.


Suzanne George, MD, assistant professor of Medicine, Harvard Medical School, clinical director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, discusses a study exploring the efficacy of a PD-1 inhibitor in patients with uterine leiomyosarcoma.

Recently published research was comprised of a collaborative effort between the sarcoma and genomics team at Dana-Farber Cancer Institute, which included a patient who achieved an exceptional response to the PD-1 inhibitor pembrolizumab (Keytruda). The patient received pembrolizumab as first-line therapy for metastatic recurrent uterine leiomyosarcoma, and had a dramatic response to the agent in multiple sites of disease—with the exception of a single site.

Researchers were ultimately able to resect that resistance site of disease, she adds. Tissue samples were gathered from her baseline tumor, which had a dramatic response, and the resistant tumor in an attempt to determine the factors for resistance. These 2 differences may help researchers understand why it became resistant.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Publication Bottom Border
Border Publication
x